Eukles Asset Management Has $937,000 Position in Masimo Co. (NASDAQ:MASI)

Eukles Asset Management cut its position in Masimo Co. (NASDAQ:MASI) by 19.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,670 shares of the medical equipment provider’s stock after selling 1,334 shares during the quarter. Eukles Asset Management’s holdings in Masimo were worth $937,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. UMB Bank n.a. grew its holdings in shares of Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 123 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 71 shares during the last quarter. Trust Co. of Vermont bought a new stake in Masimo during the 4th quarter worth approximately $33,000. NBC Securities Inc. grew its holdings in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 73 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 200 shares during the last quarter. 85.96% of the stock is owned by institutional investors.

Masimo Stock Down 2.1 %

Masimo stock opened at $176.16 on Monday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm’s fifty day moving average is $171.63 and its 200 day moving average is $147.10. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $183.14. The company has a market capitalization of $9.43 billion, a PE ratio of 121.49 and a beta of 1.02.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on MASI. Piper Sandler boosted their target price on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Wells Fargo & Company upped their price objective on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd. Finally, BTIG Research upped their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $191.40.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.